Patrick Burnett

ORCID: 0000-0002-7123-9161
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dermatology and Skin Diseases
  • Psoriasis: Treatment and Pathogenesis
  • Nail Diseases and Treatments
  • Autoimmune Bullous Skin Diseases
  • Asthma and respiratory diseases
  • Pharmaceutical studies and practices
  • Poxvirus research and outbreaks
  • Social and Cultural Dynamics
  • Antifungal resistance and susceptibility
  • Food Allergy and Anaphylaxis Research
  • Phosphodiesterase function and regulation
  • Transgenic Plants and Applications
  • Health Systems, Economic Evaluations, Quality of Life
  • Cholinesterase and Neurodegenerative Diseases
  • Beetle Biology and Toxicology Studies
  • Infectious Diseases and Mycology
  • Urticaria and Related Conditions
  • Bacillus and Francisella bacterial research
  • Allergic Rhinitis and Sensitization
  • Cutaneous lymphoproliferative disorders research
  • Contact Dermatitis and Allergies
  • Sexuality, Behavior, and Technology
  • Critical Realism in Sociology
  • Fungal Biology and Applications
  • Cancer Diagnosis and Treatment

Atara Biotherapeutics (United States)
2021-2025

University of British Columbia
2014-2021

Rady Children's Hospital-San Diego
2021

University of California, San Diego
2021

University of Miami
2021

Children's Hospital of Philadelphia
2021

Novartis Institutes for BioMedical Research
2012

Novartis (Switzerland)
2012

Kamehameha Schools
2011

Vanderbilt University
2011

Importance Once-daily roflumilast cream, 0.3%, a potent phosphodiesterase 4 inhibitor, demonstrated efficacy and was well tolerated in phase 2b trial of patients with psoriasis. Objective To evaluate the applied once daily for 8 weeks 2 trials plaque Design, Setting, Participants Two 3, randomized, double-blind, controlled, multicenter (DERMIS-1 [trial 1; n = 439] DERMIS-2 2; 442]) were conducted at 40 centers (trial 1) 39 2) US Canada between December 9, 2019, November 16, 2020, 23,...

10.1001/jama.2022.15632 article EN cc-by JAMA 2022-09-20

Background The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. Objective Roflumilast foam 0.3% is being investigated as a treatment for seborrheic dermatitis (SD). Methods In this phase 3, double-blinded trial, patients with SD were randomly assigned (2:1 ratio) to once-daily or vehicle 8 weeks. primary efficacy outcome was Investigator Global Assessment (IGA) Success at week 8, defined IGA of 0 (Clear) 1 (Almost Clear) plus ≥2-point...

10.1016/j.jaad.2023.12.065 article EN cc-by Journal of the American Academy of Dermatology 2024-01-21

Importance Safe, effective, and well-tolerated topical treatment options available for long-term use in patients with atopic dermatitis (AD) are limited associated low adherence rates. Objective To evaluate efficacy safety of once-daily roflumilast cream, 0.15%, vs vehicle cream AD. Design, Setting, Participants Two phase 3, randomized, double-blind, vehicle-controlled trials (Interventional Trial Evaluating Roflumilast Cream the Treatment Atopic Dermatitis 1 2 [INTEGUMENT-1 INTEGUMENT-2]),...

10.1001/jamadermatol.2024.3121 article EN JAMA Dermatology 2024-09-18

Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety.To assess safety and of roflumilast foam, 0.3%, in adult patients with affecting the scalp, face, trunk.This multicenter (24 sites US Canada) phase 2a, parallel group, double-blind, vehicle-controlled clinical trial was conducted between November 12, 2019, August 21, 2020. Participants were (aged ≥18 years) a diagnosis 3-month or longer duration Investigator Global Assessment (IGA) score 3...

10.1001/jamadermatol.2023.0846 article EN cc-by-nc-nd JAMA Dermatology 2023-05-03

Abstract Many health scholars find that Pierre Bourdieu's theory of practice leaves too little room for individual agency. We contend that, by virtue its relational, field‐theoretic underpinnings, the idea leaving agency in is misguided. With manifested interactions and social structures consisting relations built upon relations, stark distinction between structure inherent to substantialist thinking undermined, even dissolved, a relational context. also when treated as relationally bound...

10.1111/1467-9566.12105 article EN Sociology of Health & Illness 2014-01-21

ABSTRACT Background/Objectives Efficacy and safety of roflumilast cream 0.15% were demonstrated in patients aged ≥ 6 years with atopic dermatitis (AD) two Phase 3 trials. This parallel‐group, double‐blind trial (INTEGUMENT‐PED; NCT04845620) compared the efficacy 0.05% a vehicle 2–5 AD. Methods Patients mild‐to‐moderate AD treated once‐daily or for 4 weeks. The primary endpoint was Validated Investigator Global Assessment (vIGA‐AD) Success (0 [Clear] 1 [Almost Clear] plus 2‐grade improvement...

10.1111/pde.15840 article EN cc-by-nc Pediatric Dermatology 2025-02-20

Scalp psoriasis affects most patients with psoriasis, but it can be difficult to treat.To evaluate the efficacy and safety of once-daily roflumilast foam 0.3% on scalp body psoriasis.In a phase IIb randomized controlled trial, adults adolescents aged ≥ 12 years were (2 : 1) or vehicle for 8 weeks. The primary endpoint was Investigator Global Assessment (S-IGA) success (score 'clear' 'almost clear' plus 2-grade improvement from baseline) at week 8. Safety tolerability also...

10.1093/bjd/ljad182 article EN cc-by British Journal of Dermatology 2023-06-05

Most patients with chronic plaque psoriasis receive topical treatment; however, available options lack a balance of efficacy long-term safety and tolerability. Roflumilast cream 0.3% is highly potent phosphodiesterase 4 (PDE4) inhibitor approved by the US FDA for treatment psoriasis. The aim this study was to define pharmacokinetic (PK) profile roflumilast delivered topically from phase I maximal usage data II III studies. PK active metabolite, N-oxide, were determined applied once daily 14...

10.1007/s40257-022-00741-9 article EN cc-by-nc American Journal of Clinical Dermatology 2022-11-24

Molluscum contagiosum (MC) is a common viral skin infection that primarily affects children. Cantharidin, topical vesicant, has long history of use for MC in compounded formulations, but the safety and efficacy doses, regimens, application methods have not been demonstrated large-scale trials.To determine VP-102, drug-device combination containing cantharidin, 0.7% (w/v), compared with vehicle individuals MC.Two phase 3, randomized, double-blind, vehicle-controlled trials identical design...

10.1001/jamadermatol.2020.3238 article EN JAMA Dermatology 2020-09-23

Background/purpose Three‐dimensional (3D) imaging of the skin is a challenging technique. A new 3D digital camera system has been developed that enables reconstruction and subsequently allows volumetric quantification. Herein we present validation data on calibrated phantoms clinical application this technology. Methods Absolute relative geometric measurements were validated with static phantom manufactured by metrology institution dynamic adjustable for different volume quantities,...

10.1111/j.1600-0846.2012.00625.x article EN Skin Research and Technology 2012-06-20

e21113 Background: Common side effects of tyrosine kinase inhibitors (TKIs) such as SU include HFS and related skin toxicities. is a multitargeted inhibitor VEGFR, PDGFR KIT, standard care for the treatment advanced RCC imatinib-resistant/intolerant GIST. In this retrospective analysis, correlations between SU-associated efficacy endpoints were investigated in mRCC GIST pts from 5 4 clinical trials, respectively. Methods: Analyses included data 1,186 with (n=770) or (n=416) who received...

10.1200/jco.2011.29.15_suppl.e21113 article EN Journal of Clinical Oncology 2011-05-20

This post hoc analysis evaluated efficacy and safety of roflumilast cream in patients with psoriasis involving the face/neck or intertriginous areas from a phase IIb trial. Of 331 enrolled trial, 160 had and/or areas. Once-daily was well tolerated across multiple endpoints these patients.

10.1093/bjd/ljad060 article EN cc-by British Journal of Dermatology 2023-03-09

The Ottawa Charter for Health Promotion exhibits a substantialist approach to the agency-structure dichotomy. From point of view, both individual agency and social structure come preformed subsequently relate influence one another, starkly positioning choices made by individuals against structured sets opportunities constraints in reference which are made. relational perspective, however, relations between elements, not elements themselves, primary ontological focus. We advocate...

10.1093/heapro/dau068 article EN Health Promotion International 2014-07-30

Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence support its safety and efficacy. VP-102 is a shelf-stable drug–device combination product that contains topical (0.7% weight/volume [w/v]) being evaluated the treatment of molluscum. Our objective was present pooled efficacy analyses in compared with vehicle. Participants aged ≥ 2 years were randomized 3:2 administration or vehicle two randomized, double-blind,...

10.1007/s40257-020-00570-8 article EN cc-by-nc American Journal of Clinical Dermatology 2021-02-18

Pierre Bourdieu's theory of practice situates social practices in the relational interplay between experiential mental phenomena (habitus), resources (capitals) and objective structures (fields). When applied to class-based particular, overarching field power within which classes are potentially made manifest is primary interest. Applying statistical techniques original survey data from Toronto Vancouver, Canada, we investigated whether smoking, engaging physical activity consuming fruit...

10.1111/1467-9566.12544 article EN Sociology of Health & Illness 2017-03-23
Coming Soon ...